Galena Biopharma has acquired Mills Pharmaceuticals, gaining worldwide rights to GALE-401 (Anagrelide CR), a controlled release formulation of anagrelide. Galena plans to pursue the expedited 505(b)(2) regulatory pathway for approval of GALE-401 for the treatment of Essential Thrombocythemia (ET), as well as orphan drug status. GALE-401 has an estimated market value of approximately $200 million in the U.S., according to the company.   Mills Pharmaceuticals received an upfront payment and is eli...